Lumykras is a cancer medicine used to treat adults with non-small cell lung cancer (NSCLC) when the cancer is advanced, and its cells have a particular genetic change. The change is in the gene KRAS and is known as ‘KRAS G12C’. Lumykras is given when the disease has progressed after receiving systemic treatment (treatment affecting the whole body). Lumykras contains the active substance sotorasib.
Therapeutic Indication
### Therapeutic indication Lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.
Therapeutic Area (MeSH)
ATC Code
L01XX73
ATC Item
sotorasib
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| sotorasib | N/A | 索托拉西布 |
EMA Name
Lumykras
Medicine Name
Lumykras
Aliases
N/ANo risk management plan link.
